Bidil (Isosorbide Dinit/Hydralazine) Patent Expiration, LOE Window & CMS Spending

Bidil (Isosorbide Dinit/Hydralazine) by Azurity: Off-Patent Genericized (AB Competition), 2 AB generics, $947K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN020727 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$947K
2024 Medicare Part D Spend$520K
2024 Medicaid Spend$428K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.5% 2-yr change)